NOMINATION RIGHTS AGREEMENTNomination Rights Agreement • February 13th, 2019 • Omega Fund IV, L.P. • Pharmaceutical preparations • British Columbia
WHEREAS the Investor desires to purchase an aggregate of 20,000,000 securities comprised of a combination of Shares and pre-funded common share purchase warrants of the Corporation (the “Investment”) as part of a larger offering of Shares and pre-funded common share purchase warrants of the Corporation by way of a second amended and restated prospectus supplement dated January 5, 2018 to a short form base shelf prospectus dated December 22, 2015.
13G13g Agreement • January 22nd, 2016 • Omega Fund IV, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Essa Pharma, Inc.
JOINT FILING AGREEMENTJoint Filing Agreement • February 13th, 2019 • Omega Fund IV, L.P. • Pharmaceutical preparations
Joint Filing Agreement, dated as of February 13, 2019, is by and among the various reporting persons that are listed in the signature blocks below (the “Omega Filers”).
AGREEMENTSchedule 13g Agreement • February 10th, 2016 • Omega Fund IV, L.P. • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Egalet Corporation.
AGREEMENTAgreement • February 13th, 2019 • Omega Fund IV, L.P. • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Translate Bio, Inc.
